Ipsen Initiates Two Studies to Evaluate Carcinoid Drug

18 March 2010 (Last Updated March 18th, 2010 18:30)

Ipsen has initiated two Phase II clinical studies to evaluate the efficacy and safety of BIM 23A760, a new drug to treat patients suffering from carcinoid syndrome due to neuroendocrine tumours. Acromegaly is a rare disorder caused by the over-production of growth hormone due to a beni

Ipsen has initiated two Phase II clinical studies to evaluate the efficacy and safety of BIM 23A760, a new drug to treat patients suffering from carcinoid syndrome due to neuroendocrine tumours.

Acromegaly is a rare disorder caused by the over-production of growth hormone due to a benign tumour of the anterior pituitary gland.

The BIM 23A760 has been developed by Ipsen using its validated peptide engineering platform.

The BIM 23A760 is based on a novel concept in molecular biology involving amplification of intracellular signalling when engaging two receptors with their ligands.

Aside from the symptomatic treatment of carcinoid syndrome due to neuroendocrine tumours and acromegaly, BIM 23A760 may reduce the tumour size, Ipsen said.